170 related articles for article (PubMed ID: 16858628)
1. Low frequency of CHEK2 mutations in familial pancreatic cancer.
Bartsch DK; Krysewski K; Sina-Frey M; Fendrich V; Rieder H; Langer P; Kress R; Schneider M; Hahn SA; Slater EP
Fam Cancer; 2006; 5(4):305-8. PubMed ID: 16858628
[TBL] [Abstract][Full Text] [Related]
2. The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome.
Lener MR; Kashyap A; Kluźniak W; Cybulski C; Soluch A; Pietrzak S; Huzarski T; Gronwald J; Lubiński J
Cancer Res Treat; 2017 Apr; 49(2):430-436. PubMed ID: 27488870
[TBL] [Abstract][Full Text] [Related]
3. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.
Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H
Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889
[TBL] [Abstract][Full Text] [Related]
4. CHEK2 1100delC is not a risk factor for male breast cancer population.
Syrjäkoski K; Kuukasjärvi T; Auvinen A; Kallioniemi OP
Int J Cancer; 2004 Jan; 108(3):475-6. PubMed ID: 14648717
[TBL] [Abstract][Full Text] [Related]
5. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
6. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
[TBL] [Abstract][Full Text] [Related]
7. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
[TBL] [Abstract][Full Text] [Related]
8. CHEK2 1100delC and male breast cancer in the Netherlands.
Wasielewski M; den Bakker MA; van den Ouweland A; Meijer-van Gelder ME; Portengen H; Klijn JG; Meijers-Heijboer H; Foekens JA; Schutte M
Breast Cancer Res Treat; 2009 Jul; 116(2):397-400. PubMed ID: 18759107
[TBL] [Abstract][Full Text] [Related]
9. Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.
Iniesta MD; Gorin MA; Chien LC; Thomas SM; Milliron KJ; Douglas JA; Merajver SD
Cancer Genet Cytogenet; 2010 Oct; 202(2):136-40. PubMed ID: 20875877
[TBL] [Abstract][Full Text] [Related]
10. German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer.
Rashid MU; Jakubowska A; Justenhoven C; Harth V; Pesch B; Baisch C; Pierl CB; Brüning T; Ko Y; Benner A; Wichmann HE; Brauch H; Hamann U;
Eur J Cancer; 2005 Dec; 41(18):2896-903. PubMed ID: 16239104
[TBL] [Abstract][Full Text] [Related]
11. Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype.
van Puijenbroek M; van Asperen CJ; van Mil A; Devilee P; van Wezel T; Morreau H
J Pathol; 2005 Jun; 206(2):198-204. PubMed ID: 15818573
[TBL] [Abstract][Full Text] [Related]
12. Chromosomal radiosensitivity of breast cancer with a CHEK2 mutation.
Baeyens A; Claes K; Willems P; De Ruyck K; Thierens H; Vral A
Cancer Genet Cytogenet; 2005 Dec; 163(2):106-12. PubMed ID: 16337852
[TBL] [Abstract][Full Text] [Related]
13. Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women.
Friedrichsen DM; Malone KE; Doody DR; Daling JR; Ostrander EA
Breast Cancer Res; 2004; 6(6):R629-35. PubMed ID: 15535844
[TBL] [Abstract][Full Text] [Related]
14. Contribution of the CHEK2 1100delC variant to risk of multiple colorectal adenoma and carcinoma.
Lipton L; Fleischmann C; Sieber OM; Thomas HJ; Hodgson SV; Tomlinson IP; Houlston RS
Cancer Lett; 2003 Oct; 200(2):149-52. PubMed ID: 14568168
[TBL] [Abstract][Full Text] [Related]
15. CHEK2 gene alterations in the forkhead-associated domain, 1100delC and del5395 do not modify the risk of sporadic pancreatic cancer.
Mohelnikova-Duchonova B; Havranek O; Hlavata I; Foretova L; Kleibl Z; Pohlreich P; Soucek P
Cancer Epidemiol; 2010 Oct; 34(5):656-8. PubMed ID: 20643596
[TBL] [Abstract][Full Text] [Related]
16. Limited relevance of the CHEK2 gene in hereditary breast cancer.
Dufault MR; Betz B; Wappenschmidt B; Hofmann W; Bandick K; Golla A; Pietschmann A; Nestle-Krämling C; Rhiem K; Hüttner C; von Lindern C; Dall P; Kiechle M; Untch M; Jonat W; Meindl A; Scherneck S; Niederacher D; Schmutzler RK; Arnold N
Int J Cancer; 2004 Jun; 110(3):320-5. PubMed ID: 15095295
[TBL] [Abstract][Full Text] [Related]
17. CHEK2*1100delC does not contribute to risk to breast cancer among Malay, Chinese and Indians in Malaysia.
Thirthagiri E; Cheong LS; Yip CH; Teo SH
Fam Cancer; 2009; 8(4):355-8. PubMed ID: 19399639
[TBL] [Abstract][Full Text] [Related]
18. CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer.
Wasielewski M; Vasen H; Wijnen J; Hooning M; Dooijes D; Tops C; Klijn JG; Meijers-Heijboer H; Schutte M
Clin Cancer Res; 2008 Aug; 14(15):4989-94. PubMed ID: 18676774
[TBL] [Abstract][Full Text] [Related]
19. CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden.
Wagenius M; Borg A; Johansson L; Giwercman A; Bratt O
Scand J Urol Nephrol; 2006; 40(1):23-5. PubMed ID: 16452051
[TBL] [Abstract][Full Text] [Related]
20. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.
Adank MA; Jonker MA; Kluijt I; van Mil SE; Oldenburg RA; Mooi WJ; Hogervorst FB; van den Ouweland AM; Gille JJ; Schmidt MK; van der Vaart AW; Meijers-Heijboer H; Waisfisz Q
J Med Genet; 2011 Dec; 48(12):860-3. PubMed ID: 22058428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
